BUSINESS

• Daiichi Sankyo to Divest Espha Generic Unit for 25 Billion Yen
  May 16, 2023

• Sumitomo Incurs 77 Billion Yen Operating Loss in FY2022 on Kynmobi Impairment Charge
  May 16, 2023

• 400 Staffers Pitching Leqembi in US, Tapping Digital Tools: Eisai CEO
  May 16, 2023

• Eisai’s FY2022 Sales Slip 1.6% on Lower Milestones, Year-Before Gain
  May 16, 2023

• FDA Approves Astellas’ Blockbuster Hopeful for Hot Flash Treatment
  May 16, 2023

• Keytruda-Chemo Combo Filed for 1st Line Gastric Cancer in Japan: MSD
  May 15, 2023

• Mitsubishi Tanabe Logs 38% Growth in Full-Year Sales, Returns to Profitability on Gilenya Royalties
  May 15, 2023

• Otsuka’s Q1 Pharma Sales Climb 20.3% Buoyed by Global Products
  May 15, 2023

• Takeda Logs Record Sales, Breaks 4 Trillion Yen Mark in FY2022
  May 12, 2023

• Astellas Loses Appeal Bid in Lexiscan Patent Infringement; Ruling Finalized
  May 12, 2023

• Oral Radicava Approved in Switzerland: Mitsubishi Tanabe
  May 12, 2023

• Rexulti Snags US Approval for Alzheimer’s Agitation: Otsuka/Lundbeck
  May 12, 2023

• Xocova’s Uptake in Japan in Line with Expectations: Shionogi CEO
  May 11, 2023

• Kyowa Kirin Axes Flagship Kidney Disease Drug Candidate
  May 11, 2023

• Kyowa Kirin Cuts Net Profit Forecast after Kidney Disease Drug Jettisoned
  May 11, 2023

• Shionogi Hits Record High Earnings on Xocova Boon in FY2022
  May 11, 2023

• Opdivo-Yervoy Shows Similar Mortality Rates in Registration Trial and RWD: Ono
  May 11, 2023

• Opdivo’s Japan Patent to Expire in 2031, Ono to Cover LOE with New Launches: Chief
  May 11, 2023

• Ono Notches Two-Digit Growth in FY2022; Opdivo en Route to 150 Billion Yen Mark
  May 11, 2023

• Japan Ethical Drug Sales Surge 3.9% in March: Crecon
  May 11, 2023

ページ

• « 先頭
• ‹ Prev
• …
• 136
• 137
• 138
• 139
• 140
• 141
• 142
• 143
• 144
• …
• Next ›
• 最終 »